| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/09168451.2016.1248369 |
| P698 | PubMed publication ID | 27885931 |
| P2093 | author name string | Masayuki Igarashi | |
| P2860 | cites work | OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice | Q21090145 |
| Avermectins, New Family of Potent Anthelmintic Agents: Producing Organism and Fermentation | Q24598202 | ||
| PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release | Q24654913 | ||
| A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis | Q28139874 | ||
| The diarylquinoline TMC207 for multidrug-resistant tuberculosis | Q28247333 | ||
| Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection | Q28480875 | ||
| A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis | Q29617342 | ||
| Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis | Q34272283 | ||
| Novel semisynthetic antibiotics from caprazamycins A-G: caprazene derivatives and their antibacterial activity | Q34335455 | ||
| Dysregulation of bacterial proteolytic machinery by a new class of antibiotics | Q34456129 | ||
| In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs | Q34722433 | ||
| Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs | Q35758996 | ||
| Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model | Q37144892 | ||
| Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45 | Q37234023 | ||
| Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resista | Q38964133 | ||
| Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis | Q39321112 | ||
| In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species | Q40750034 | ||
| Activity of BB-K8 (amikacin) against clinical isolates resistant to one or more aminoglycoside antibiotics | Q40942941 | ||
| Chemical and physical characterization of capreomycin | Q43984873 | ||
| Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp. | Q55036785 | ||
| P433 | issue | 1 | |
| P921 | main subject | natural product | Q901227 |
| P304 | page(s) | 32-37 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Bioscience, Biotechnology, and Biochemistry | Q11192374 |
| P1476 | title | Development of new antituberculosis drugs from natural products | |
| P478 | volume | 81 |
| Q47594312 | New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development | cites work | P2860 |
Search more.